Abraham Chaibi is cofounder and CEO of Sapho Bio. The San Carlos company automates qc workflows for pharmaceutical companies and serves 30 enterprise customers. Its rapid sterility method returns results in 2 days, compared with 14 for the standard USP<71> method.
He arrived at biotech through software. As cofounder and CTO of Dexterity Capital from 2017 to 2024, he led the engineering behind the firm's low-latency trading platform, which traded more than $2 trillion and managed $300 million. Earlier, he built data systems at LiveRamp and worked on optimization problems, NFL scheduling among them, for an analytics consultancy.
Abraham holds a BSE in mechanical engineering, cum laude. He is a licensed pilot.
Cofounded a San Carlos lab automation company rebuilding independent testing workflows, starting with pharmaceutical products. Sapho Bio runs USP-validated lot release and stability studies, and its rapid sterility method returns results in 2 days compared with 14 for the standard USP<71> method. Grew the customer base to 30 enterprises and thousands of tests processed each month.
Company Description
Pharmaceutical testing lab in San Carlos, California, combining AI tooling with automated hardware.